138 related articles for article (PubMed ID: 17460930)
21. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists.
Gómez-Reino J; Carmona L
Acta Reumatol Port; 2006; 31(3):201-3. PubMed ID: 17094331
[No Abstract] [Full Text] [Related]
22. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
Carroll MB; Bond MI
Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
[TBL] [Abstract][Full Text] [Related]
23. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers.
Cobanoglu N; Ozcelik U; Kalyoncu U; Ozen S; Kiraz S; Gurcan N; Kaplan M; Dogru D; Yalcin E; Pekcan S; Kose M; Topaloglu R; Besbas N; Bakkaloglu A; Kiper N
Int J Tuberc Lung Dis; 2007 Nov; 11(11):1177-82. PubMed ID: 17958978
[TBL] [Abstract][Full Text] [Related]
24. Reactivation of tuberculosis by tumor necrosis factor neutralization.
Jacobs M; Samarina A; Grivennikov S; Botha T; Allie N; Fremond C; Togbe D; Vasseur V; Rose S; Erard F; Monteiro A; Quesniaux V; Ryffel B
Eur Cytokine Netw; 2007 Mar; 18(1):5-13. PubMed ID: 17400533
[TBL] [Abstract][Full Text] [Related]
25. Treatment with anti-TNF alpha does not induce reactivation of latent Salmonella enterica serovar Typhimurium infection in C3H/HeN mice.
van Diepen A; Martina CA; Flierman R; Janssen R; van Dissel JT
Scand J Immunol; 2007 May; 65(5):407-11. PubMed ID: 17444950
[TBL] [Abstract][Full Text] [Related]
26. [Tuberculosis in the 21st century].
Yossepowitch O; Dan M
Harefuah; 2007 Mar; 146(3):206-11, 245. PubMed ID: 17460929
[TBL] [Abstract][Full Text] [Related]
27. Tuberculosis in patients treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?
Rojas-Villarraga A; Agudelo CA; Pineda-Tamayo R; Porras A; Matute G; Anaya JM
Biomedica; 2007 Jun; 27(2):159-71. PubMed ID: 17713627
[TBL] [Abstract][Full Text] [Related]
28. Latent infection and tuberculosis disease in rheumatoid arthritis patients.
Acevedo-Vásquez E; Ponce de León D; Gamboa-Cárdenas R
Rheum Dis Clin North Am; 2009 Feb; 35(1):163-81. PubMed ID: 19481003
[TBL] [Abstract][Full Text] [Related]
29. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay.
Matulis G; Jüni P; Villiger PM; Gadola SD
Ann Rheum Dis; 2008 Jan; 67(1):84-90. PubMed ID: 17644549
[TBL] [Abstract][Full Text] [Related]
30. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
31. Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis.
Epstein D; Watermeyer G; Kirsch R
Aliment Pharmacol Ther; 2007 Jun; 25(12):1373-88. PubMed ID: 17539977
[TBL] [Abstract][Full Text] [Related]
32. Tumour necrosis factor inhibitors in ankylosing spondylitis.
Reed MR; Taylor AL
Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
[TBL] [Abstract][Full Text] [Related]
33. Antitumor necrosis factor-alpha therapy and potential cancer inhibition.
Williams GM
Eur J Cancer Prev; 2008 Apr; 17(2):169-77. PubMed ID: 18287875
[TBL] [Abstract][Full Text] [Related]
34. Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era.
Nacci F; Matucci-Cerinic M
Best Pract Res Clin Rheumatol; 2011 Jun; 25(3):375-88. PubMed ID: 22100287
[TBL] [Abstract][Full Text] [Related]
35. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.
Wallis RS
Lancet Infect Dis; 2008 Oct; 8(10):601-11. PubMed ID: 18922482
[TBL] [Abstract][Full Text] [Related]
36. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases.
Soborg B; Ruhwald M; Hetland ML; Jacobsen S; Andersen AB; Milman N; Thomsen VO; Jensen DV; Koch A; Wohlfahrt J; Ravn P
J Rheumatol; 2009 Sep; 36(9):1876-84. PubMed ID: 19648300
[TBL] [Abstract][Full Text] [Related]
37. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
[TBL] [Abstract][Full Text] [Related]
38. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.
Aggarwal R; Manadan AM; Poliyedath A; Sequeira W; Block JA
J Rheumatol; 2009 May; 36(5):914-7. PubMed ID: 19332623
[TBL] [Abstract][Full Text] [Related]
39. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis.
Plessner HL; Lin PL; Kohno T; Louie JS; Kirschner D; Chan J; Flynn JL
J Infect Dis; 2007 Jun; 195(11):1643-50. PubMed ID: 17471434
[TBL] [Abstract][Full Text] [Related]
40. Novel screening tools for latent tuberculosis: time to leave an old friend?
Villiger PM; Zellweger JP; Möller B
Curr Opin Rheumatol; 2009 May; 21(3):238-43. PubMed ID: 19346950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
